Or­biMed's TKI play makes its Nas­daq de­but as The­seus prices IPO

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

A Boston biotech with a hefty back­ing from Or­biMed is mak­ing its Nas­daq de­but Thurs­day.

The­seus Phar­ma­ceu­ti­cals priced its IPO at $16 per share, the high end of its range, jump­ing to the pub­lic mar­ket rough­ly six months af­ter Or­biMed led the biotech’s nine-fig­ure Se­ries B. The­seus net­ted $160 mil­lion for the pub­lic of­fer­ing, bring­ing the sec­tor’s to­tal com­bined 2021 raise to $13.74 bil­lion across 86 dif­fer­ent com­pa­nies, per the End­points News tal­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER